Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Recent progress in understanding immune activation in the pathogenesis in HIV–tuberculosis co-infection

du Bruyn, Elsaa,*; Peton, Nashieda,b,*; Esmail, Hanifa,c; Howlett, Patrick J.a,d; Coussens, Anna K.a,b,e,f; Wilkinson, Robert J.a,d,g

Current Opinion in HIV and AIDS: November 2018 - Volume 13 - Issue 6 - p 455–461
doi: 10.1097/COH.0000000000000501
TUBERCULOSIS AND HIV: Edited by Richard E. Chaisson and Haileyesus Getahun

Purpose of review Tuberculosis is the leading infectious cause of death worldwide, and HIV-1 the best recognized risk factor for active TB. This review focuses on immune complex formation; the interplay of type I and II interferon signaling; and T-cell activation in HIV–TB pathogenesis.

Recent findings Circulating immune complexes and complement, and Fcγ signaling in whole blood act as early markers of TB disease in HIV-1-infected persons. HIV-1 is associated with a type I interferon response in whole blood, reducing the specificity of TB biomarkers dependent on type I and II interferon genes. Type I and type II interferons are implicated in both protection and TB disease, a protective outcome may depend on modulating these pathways. Whilst M. tuberculosis-specific CD4 T cells are preferentially depleted during HIV-1 infection, activation markers on M. tuberculosis-specific CD4 T cells, in particular HLA-DR, reflect immune activation and have promise as biomarkers of M. tuberculosis disease activity in individuals with HIV-1.

Summary TB pathogenesis in HIV-1 involves a complex interaction of underlying activation of both the innate and adaptive immune systems. Further research is required to understand whether biomarkers of activation could be used to predict or quantify TB disease in the context of HIV-1 infection.

aWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine

bDivision of Medical Microbiology, Department of Pathology, University of Cape Town, Observatory, South Africa

cRadcliffe Department of Medicine, University of Oxford

dDepartment of Medicine, Imperial College London, London, United Kingdom

eWalter and Eliza Hall Institute of Medical Research

fDivision of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia

gThe Francis Crick Institute, London, United Kingdom

Correspondence to Patrick J. Howlett, Mb Chb, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa. E-mail: patrick.howlett@gmail.com

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.